Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Cabotegravir (oral) and cabotegravir/rilpivirine (long acting)

Thursday 02 April 2020

Two new HIV drugs have been added to the interaction checker. Cabotegravir (oral tablets; Vocabria®) and cabotegravir/rilpivirine (extended-release injectable suspensions; Cabenuva®) have been approved for use in Canada.

For the time being, only summaries of the interactions are available. We will add full references when American and/or European product labels are available (in line with our standard referencing procedure). The new drugs are also available on the iChart app, but unfortunately to our work on COVID-19 interactions, updates to the interaction charts and treatment selectors are not currently available but will be added as soon as our workload allows.

The Canadian Product Monograph for the two formulations is available from ViiV Healthcare’s Canadian website.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017
building_better_healthcare_awards_2016 healthline-best-HIV-and-AIDS-apps-of-2016